PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Progress Toward Containment of Poliovirus Type 2 - Worldwide, 2017.

Abstract The Global Polio Eradication Initiative (GPEI) continues to make progress toward the eradication target. Only one of the three serotypes, wild poliovirus (WPV) type 1 (WPV1), is still circulating, and the numbers of cases and countries with endemic transmission are at record lows. With the certification of wild poliovirus type 2 (WPV2) eradication in 2015 and the global replacement of trivalent oral poliovirus vaccine (tOPV) containing Sabin poliovirus types 1, 2, and 3 with bivalent OPV containing only Sabin poliovirus types 1 and 3 during April-May 2016, poliovirus type 2 (PV2) is now an eradicated pathogen. However, in eight countries (Cameroon, Chad, Democratic Republic of Congo, Mozambique, Niger, Nigeria, Pakistan, and Syria), monovalent type 2 OPV (mOPV2) was authorized for large-scale outbreak control after tOPV withdrawal (1). Poliovirus containment, an evolving area of work that affects every country, aims to ensure that all PV2 specimens are safely contained to minimize the risk for reintroducing the virus into communities. This report summarizes the current status of poliovirus containment and progress since the last report (2), and outlines remaining challenges. Within 30 countries, 86 facilities have been designated by the relevant national authorities (usually the Ministry of Health) to become poliovirus-essential facilities for the continued storage or handling of PV2 materials; each country is responsible for ensuring that these facilities meet all biorisk management requirements.
PMID
Related Publications

Progress Toward Polio Eradication - Worldwide, 2015-2016.

Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.

Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.

Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 - Worldwide, 2016-2017.

World Health Organization Guidelines for Containment of Poliovirus Following Type-Specific Polio Eradication - Worldwide, 2015.

Authors

Mayor MeshTerms

Disease Eradication

Keywords
Journal Title mmwr. morbidity and mortality weekly report
Publication Year Start




PMID- 28640795
OWN - NLM
STAT- MEDLINE
DA  - 20170622
DCOM- 20170623
LR  - 20170623
IS  - 1545-861X (Electronic)
IS  - 0149-2195 (Linking)
VI  - 66
IP  - 24
DP  - 2017 Jun 23
TI  - Progress Toward Containment of Poliovirus Type 2 - Worldwide, 2017.
PG  - 649-652
LID - 10.15585/mmwr.mm6624a5 [doi]
AB  - The Global Polio Eradication Initiative (GPEI) continues to make progress toward 
      the eradication target. Only one of the three serotypes, wild poliovirus (WPV)
      type 1 (WPV1), is still circulating, and the numbers of cases and countries with 
      endemic transmission are at record lows. With the certification of wild
      poliovirus type 2 (WPV2) eradication in 2015 and the global replacement of
      trivalent oral poliovirus vaccine (tOPV) containing Sabin poliovirus types 1, 2, 
      and 3 with bivalent OPV containing only Sabin poliovirus types 1 and 3 during
      April-May 2016, poliovirus type 2 (PV2) is now an eradicated pathogen. However,
      in eight countries (Cameroon, Chad, Democratic Republic of Congo, Mozambique,
      Niger, Nigeria, Pakistan, and Syria), monovalent type 2 OPV (mOPV2) was
      authorized for large-scale outbreak control after tOPV withdrawal (1). Poliovirus
      containment, an evolving area of work that affects every country, aims to ensure 
      that all PV2 specimens are safely contained to minimize the risk for
      reintroducing the virus into communities. This report summarizes the current
      status of poliovirus containment and progress since the last report (2), and
      outlines remaining challenges. Within 30 countries, 86 facilities have been
      designated by the relevant national authorities (usually the Ministry of Health) 
      to become poliovirus-essential facilities for the continued storage or handling
      of PV2 materials; each country is responsible for ensuring that these facilities 
      meet all biorisk management requirements.
FAU - Previsani, Nicoletta
AU  - Previsani N
FAU - Singh, Harpal
AU  - Singh H
FAU - St Pierre, Jeanette
AU  - St Pierre J
FAU - Boualam, Liliane
AU  - Boualam L
FAU - Fournier-Caruana, Jacqueline
AU  - Fournier-Caruana J
FAU - Sutter, Roland W
AU  - Sutter RW
FAU - Zaffran, Michel
AU  - Zaffran M
CN  - MEng
LA  - eng
PT  - Journal Article
DEP - 20170623
PL  - United States
TA  - MMWR Morb Mortal Wkly Rep
JT  - MMWR. Morbidity and mortality weekly report
JID - 7802429
SB  - IM
MH  - *Disease Eradication
MH  - Global Health/*statistics & numerical data
MH  - Humans
MH  - Poliomyelitis/epidemiology/*prevention & control
EDAT- 2017/06/24 06:00
MHDA- 2017/06/24 06:01
CRDT- 2017/06/23 06:00
AID - 10.15585/mmwr.mm6624a5 [doi]
PST - epublish
SO  - MMWR Morb Mortal Wkly Rep. 2017 Jun 23;66(24):649-652. doi:
      10.15585/mmwr.mm6624a5.